Chemotherapy leads to severe nerve pain in 40% of cancer patients. Personalized treatment strategies are essential to address this global health challenge.
Around 4 in every 10 cancer patients taking chemotherapy are affected with severe peripheral nerve pain (neuropathy).
Neuropathy is a nervous disorder that causes pain, numbness, swelling, or muscle weakness in different parts of the body. The study conducted by analyzing the available evidence is published in the journal Regional Anesthesia & Pain Medicine (1✔ ✔Trusted Source
Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000-24
Go to source
).
Advertisement
Chemotherapy and Nerve Damage
Platinum-based drugs like taxanes and lung cancer are linked to higher rates of persistent neuropathy. Researchers recommend personalized pain management strategies to address the issue.
The drugs used to treat cancer damage healthy cells and tissues, including the nervous system. The effects can manifest in movement disturbances, such as loss of balance or coordination, and sensory disturbances, such as loss of sensation; numbness, tingling, “pins and needles”; or a burning sensation on the skin.
Several factors influence the frequency and severity of chronic peripheral neuropathic pain, including type and dose of chemotherapy, pre-existing neuropathy, and the use of other drugs that can damage the nervous system, explain the researchers. The condition is thought to be caused by direct peripheral nerve cell damage which disrupts or rewires normal nerve signaling pathways, resulting in persistent pain, they add.
Prompted by the growing number of cancer survivors and increasingly aggressive treatment of the disease, the researchers wanted to gauge the global prevalence of chronic painful peripheral neuropathy linked to chemotherapy.
They scoured research databases for relevant studies published between 2000 and 2024, focusing on potentially influential sociodemographic, clinical, and methodological (study design, funding source, for example) factors.
Advertisement
Cancer Patients Suffer Persistent Nerve Pain After Treatment
In all, they pooled the results of 77 eligible studies, involving 10,962 participants from 28 countries, all of whom had peripheral neuropathy that was associated with cancer drug treatment. In 4545 of these participants, this was painful and persistent, lasting for at least 3 months. The highest number of studies were carried out in the US (13) and Japan (10), and almost half were prospective observational studies.
The cancers that featured most often were those of the bowel (25; 33%) and breast (17; 22%), while the largest proportion of studies focused on patients treated with either platinum-based agents (13;17%), or taxanes (11; just over 14%), or both (6; 8%), or the FOLFOX combination of folinic acid plus 5-fluorouracil plus oxaliplatin (5; 6.5%). Pooled data analysis of the study results showed that the overall prevalence of persistent painful peripheral neuropathy was just over 41%.
When stratified further, the analysis indicated that the highest prevalence was among patients treated with platinum-based agents (40.5%) and taxanes (just over 38%). Prevalence was lowest among those treated with the FOLFOX combination (16.5%).
Advertisement
Lung Cancer Patients at Highest Risk of Nerve Pain
Prevalence was also highest among those with primary lung cancer (just over 62%), possibly because of the complexities of treatment for this disease, suggest the researchers. Prevalence was lowest among those with primary ovarian cancer (31.5%) and lymphoma (36%).
When stratified by continent, studies of patients in Asia reported the highest prevalence of persistent painful neuropathy (46.5%), while studies of patients in Europe reported the lowest (36%). Prevalence rates were similar in both men and women. The researchers emphasize that the design and methodology of the included studies differed substantially. And the overall certainty of evidence was considered to be low.
Understanding the prevalence and predictors of chronic painful chemotherapy-induced peripheral neuropathy is critical for promoting early diagnosis and developing personalized treatment strategies. “Our findings emphasize that chronic painful chemotherapy-induced peripheral neuropathy represents a substantial global health challenge, affecting more than 40% of those diagnosed with it.”
“The wide variability in prevalence rates across different countries, continents, chemotherapy regimens, and primary cancer history underscores the need for tailored strategies to address this debilitating condition.” Future studies should focus on elucidating the mechanisms underlying these disparities and developing interventions that can reduce the burden of chronic painful chemotherapy-induced peripheral neuropathy globally.
Reference:
- Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000–24 – (https://rapm.bmj.com/content/early/2025/01/06/rapm-2024-106229)
Source-Eurekalert